Exploratory Study of NS-089/NCNP-02 in DMD

Phase 1

Completed

• Conditions: Duchenne Muscular Dystrophy
• Interventions: Drug: NS-089/NCNP-02

• Registration Number: NCT04129294
• Lead Sponsor: National Center of Neurology and Psychiatry, Japan

Brief Summary

This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK) of NS-089/NCNP-02 in subjects diagnosed with Duchenne muscular dystrophy (DMD), and to determine the dosage for subsequent studies.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-10-15
• Study First Submitted QC: 2019-10-15
• Study First Posted: 2019-10-16
• Study Start: 2019-12-02
• Primary Completion: 2022-05-31
• Study Completion: 2022-05-31
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-28
• Last Update Posted: 2022-09-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Has an out of frame deletion(s) that could be corrected by skipping exon 44 as confirmed by any of methodology at the time of visit 1. If not confirmed by any of methodology that evaluates the relative copy number of all exons (i.e. MLPA etc), must be confirmed through these techniques by the time of visit 3.
• DNA sequencing of exon 44 confirms that no DNA polymorphisms occur that could compromise duplex formation between NS-089/NCNP-02 and pre-mRNA.
• Male and >= 8 years and < 17 years of age at the time of obtaining informed consent and/or assent. Subjects aged >= 4 years and < 8 years can be enrolled according to the circumstances.
• Able to give informed consent in writing signed by parent(s) or legal guardian who is able to understand all of the study procedure requirements. If applicable, able to give informed assent in writing signed by the subject.
• Life expectancy of at least 1 year
• Able to ambulate. Non-ambulant subject can be enrolled according to the circumstances.
• Have intact muscles, which have adequate quality for biopsy. (No lacks or severe atrophy of biceps brachii or tibialis anterior muscle)
• QTc <450 msec (based on 12-lead ECGs), or <480 msec for subject with Bundle Branch Block.
• Glucocorticoid-naive patients, or patients who have used systemic glucocorticoids for at least 6 months prior to enrollment in this study with no dose changes for at least 3 months prior to enrollment.

Exclusion Criteria

• Has participated in other pharmacological clinical trial that might recover dystrophin protein by the readthrough or the exon-skipping therapy, and/or upregulate the dystrophin-associated proteins such as utrophin.
• A forced vital capacity (FVC) < 50% of predicted.
• Continuous use of artificial respirator (except for use of NPPV while sleeping)
• A left ventricular ejection fraction (EF) < 40% or fractional shortening (FS) < 25% based on echocardiogram (ECHO).
• Surgery within the last 3 months prior to the first anticipated administration of study medication or planned for anytime between visit 1 of Part 1 and the last visit of Part 2.
• Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody test (HCV), or human immunodeficiency virus (HIV) test at screening.
• Current diagnosis of any immune deficiency or autoimmune disease.
• Current diagnosis of any active or uncontrolled infection, cardiomyopathy, or liver or renal disease.
• Use of any other investigational agents and/or experimental agents within 3 months prior to the first anticipated administration of study medication.
• History of any severe drug allergy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
NS-089/NCNP-02	NS-089/NCNP-02	NS-089/NCNP-02

Primary Outcome Measures

Name	Time	Method
Adverse event and adverse drug reaction [Safety and Tolerability]	At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)	adverse event and adverse drug reaction

Secondary Outcome Measures

Name	Time	Method
Expression of dystrophin protein	At the end of the treatment period (24 weeks) of Part 2	Expression of dystrophin protein
NS-089/NCNP-02 concentration of the blood plasma	At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)	NS-089/NCNP-02 concentration of the blood plasma
TTSTAND	At the end of the treatment period (24 weeks) of Part 2	Time to Stand Test
TTRW	At the end of the treatment period (24 weeks) of Part 2	Time to Run/Walk 10 Meters test
PUL	At the end of the treatment period (24 weeks) of Part 2	Performance of Upper Limb test
NSAA	At the end of the treatment period (24 weeks) of Part 2	North Star Ambulatory Assessment
6MWT and 2MWT	At the end of the treatment period (24 weeks) of Part 2	Six-Minute Walk Test (6MWT) and Two-Minute Walk Test (2MWT)
TUG	At the end of the treatment period (24 weeks) of Part 2	Timed Up \& Go (TUG) test
Detection of exon 44-skipped mRNA of dystrophin in muscle tissue	At the end of the treatment period (24 weeks) of Part 2	Detection of exon 44-skipped mRNA of dystrophin in muscle tissue
Serum Creatine kinase concentration	At the end of Part 2 (24 weeks treatment period and 12 weeks follow up period)	Serum Creatine kinase concentration

Trial Locations

Locations (1)

National Center of Neurology and Psychiatry; 🇯🇵 Kodaira, Tokyo, Japan